Regenxbio提交3亿美元混合货架产品

2025-11-27 06:34

Regenxbio (RGNX) has filed a shelf registration to offer up to $300M in securities.
The offering may include common stock, preferred stock, debt securities, warrants, rights, or units, in one or more combinations and tranches.

More on Regenxbio

REGENXBIO's Late-Stage Pipeline Momentum Strengthens After Q3 Earnings Beat
REGENXBIO Inc. (RGNX) Q3 2025 Earnings Call Transcript
Regenxbio: Poised For Breakthrough With RGX-121 Gene Therapy In Hunter Syndrome
REGENXBIO plans top-line RGX-202 Duchenne data release in early Q2 2026 while advancing toward 2027 commercial launch
Regenxbio Q3 2025 Earnings Preview